Beneficient DEF 14A proxy statements

Beneficient's proxy statement details proposals for its 2026 annual meeting, including director elections and incentive plan amendments, amidst extensive litigation, complex related-party dealings, and recent management changes.

Beneficient is seeking stockholder approval for a reverse stock split to increase its share price and maintain its Nasdaq listing, alongside an adjournment proposal.

Beneficient has closed a $1.91 million primary capital transaction by issuing Series B-8 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund, aiming to expand its alternative asset portfolio and liquidity solutions.

Beneficient has once again adjourned its Annual Meeting of Stockholders to May 29, 2025, due to an insufficient number of shares present to constitute a quorum.

Beneficient's proxy statement outlines its mission to democratize alternative asset investment for underserved investors through tools like AltQuote and AltAccess.

Beneficient (BENF) has adjourned its Annual Meeting of Stockholders for a second time to May 28, 2025, due to an insufficient number of shares present to constitute a quorum.

Beneficient closed a primary capital transaction, issuing Series B-7 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund.

Beneficient reminds stockholders to vote on proxy proposals before the upcoming Annual Meeting of Stockholders on April 30, 2025.

Beneficient (BENF) has adjourned its Annual Meeting of Stockholders for a second time to allow more time for stockholders to vote, as a sufficient quorum was not present.

Beneficient has closed a $9.6 million primary capital transaction, issuing Series B-6 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund.

Beneficient (BENF) has adjourned its annual meeting of stockholders due to insufficient shares present for a quorum and rescheduled it for April 16, 2025.

Beneficient will hold its annual stockholders meeting virtually on March 31, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Beneficient has entered into a subscription agreement with Hatteras Master Fund and its affiliates for the issuance of FLP-4 Unit Accounts and reached a settlement agreement regarding the GWG Litigation, resolving claims against the company and its officers.

Beneficient is seeking stockholder approval for a transaction to revise the liquidation priority of its subsidiary, Beneficient Company Holdings, L.P. (BCH), to enhance shareholder value and drive long-term growth.

Beneficient announced its Q3 fiscal 2025 results, highlighting a proposed transaction to increase tangible book value for public stockholders and expansion into digital asset markets.

Beneficient closed a $1.36 million primary capital transaction with 8F Fund, receiving Resettable Convertible Preferred Stock in exchange for a limited partner interest.

Beneficient enters into an agreement to amend governing documents, allowing public stockholders to share in liquidation priority, potentially increasing tangible book value and aligning interests.

Beneficient is asking stockholders to approve an amendment to its Articles of Incorporation to increase the number of authorized shares of Class A common stock from 18,750,000 to 5,000,000,000 to support its business plan, liquidity transactions, and potential capital raising activities.

Beneficient is asking stockholders to approve the issuance of Class A common stock to YA II PN, LTD. (Yorkville) under a Standby Equity Purchase Agreement (SEPA) to comply with Nasdaq Listing Rule 5635(d).

Beneficient is asking its stockholders to approve a reverse stock split at its special meeting on March 21, 2024, to boost its stock price and maintain its Nasdaq listing.

Beneficient will finance liquidity transactions for three funds managed by ff Venture Capital, potentially increasing its loan portfolio collateral by up to $121.5 million.